Home › Funds › Defilade Capital Management, L.P. › CRNX
Defilade Capital Management, L.P. position in CRNX
CRINETICS PHARMACEUTICALS IN
Defilade Capital Management, L.P. reported holding 239,440 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$9.0M, representing 1.20% of its reported portfolio and ranking #36 among its reported holdings. Defilade Capital Management, L.P. first reported this position in Q2 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Defilade Capital Management, L.P.'s CRNX position evolved
Defilade Capital Management, L.P. first disclosed a stake in CRNX in Q2 2026 at 239,440 shares (US$9.0M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 239.44K | $8.96M | New |
About CRNX and 13F data
CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 38 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRNX
- Farallon Capital Management 8.99M sh · $336.37M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 8.99M sh · $336.37M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 6.46M sh · $241.87M · Q2 2026
- Bellevue Group AG 2.62M sh · $98.04M · Q2 2026
- BAKER BROS. ADVISORS LP 2.35M sh · $87.99M · Q2 2026
- Siren, L.L.C. 1.42M sh · $53.17M · Q2 2026
- First Light Asset Management, LLC 1.36M sh · $50.92M · Q2 2026
- Novo Holdings A/S 1.32M sh · $49.39M · Q2 2026
- ADAR1 Capital Management, LLC 1.22M sh · $45.73M · Q2 2026
- MONTANOVA CAPITAL, LLC 1.19M sh · $44.39M · Q2 2026
- ORBIMED ADVISORS LLC 999.00K sh · $37.38M · Q2 2026
More on Defilade Capital Management, L.P.
FAQ
How long has Defilade Capital Management, L.P. held CRNX?
Defilade Capital Management, L.P. has disclosed CRNX holdings in 1 of the last 1 reported quarters, going back to Q2 2026.
What is Defilade Capital Management, L.P.'s current position in CRNX?
As of Q2 2026, Defilade Capital Management, L.P. holds 239.44K shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $8.96M, representing 1.20% of its reported portfolio and ranking #36.
Has Defilade Capital Management, L.P. been buying or selling CRNX?
In the latest 13F filing (Q2 2026), Defilade Capital Management, L.P. newly opened its position in CRNX.
Which other funds hold CRNX?
Other major institutional holders of CRNX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., DRIEHAUS CAPITAL MANAGEMENT LLC, among 38 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.